Clinical

Dataset Information

0

FLOX in Combination With Cetuximab in First-line Treatment of Colorectal Cancer


ABSTRACT: The main objective of this trial is to explore the effect of combining an established chemotherapy regimen (FLOX), based on 5-fluorouracil, folinic acid, and oxaliplatin (Eloxatin), with the EGF receptor antibody cetuximab (Erbitux) in first-line treatment of metastatic colorectal cancer. The trial will investigate two regimens of FLOX plus cetuximab, in which FLOX is given continuously or intermittently, compared to standard FLOX without cetuximab.

DISEASE(S): Patient With Metastatic Colorectal Cancer.,Metastatic Colorectal Cancer,Colorectal Neoplasms

PROVIDER: 2015398 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

2011-03-25 | GSE21228 | GEO
2017-03-02 | GSE63916 | GEO
2007-09-12 | GSE8967 | GEO
2013-11-18 | E-GEOD-51880 | biostudies-arrayexpress
| 2054067 | ecrin-mdr-crc
2010-12-23 | E-GEOD-26264 | biostudies-arrayexpress
2012-05-22 | E-GEOD-32975 | biostudies-arrayexpress
2013-11-18 | GSE51880 | GEO
2019-05-14 | GSE131108 | GEO
2012-12-01 | E-GEOD-36790 | biostudies-arrayexpress